Potential approaches and recent advances in biomarker discovery in autism spectrum disorders

Salloum-Asfar, Salam; Elsayed, Ahmed K.; Abdulla, Sara

doi:10.1016/b978-0-12-824421-0.00014-x

Cited by 1 publication

(2 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During childhood and adolescence, several critical brain development processes occur, and it is believed that cannabinoid-based drugs may have adverse effects on the brain (Poleg et al, 2019 ) or induce cannabis addiction. Some clinical data also support these arguments (Bailone et al, 2022 ; Parrella et al, 2023 ; Shani Poleg et al, 2019 ; Salloum-Asfar et al, 2023 ). For instance, a preclinical rodent study found that chronic application of CB2 receptors agonist WIN 55,212-2 during puberty resulted in severe behavioral disturbance in adulthood (Schneider & Koch, 2003 ; Schneider et al, 2008 ).…”

Section: Medical Cannabinoid and Risksmentioning

confidence: 89%

“…Preclinical evidence supporting a role of ECS signaling in ASD comes from studies in rodent models of MIA and neuroinflammation (Hughes et al, 2023 ; Salloum-Asfar et al, 2023 ). For example, the production of MIA-based IL-17 in response to the innate immune stimulator polyinosine:polycytidylic acid [poly(I:C)] induces abnormal cortex development and ASD-like sociability deficits in mouse offspring (Gunn et al, 2016 ).…”

Section: Microglial-endocannabinoid Signaling and Asdmentioning

confidence: 99%

See 1 more Smart Citation

Unraveling the Endocannabinoid System: Exploring Its Therapeutic Potential in Autism Spectrum Disorder

Jana,

Nath,

Sen

et al. 2024

Neuromol Med

View full text Add to dashboard Cite

The salient features of autism spectrum disorder (ASD) encompass persistent difficulties in social communication, as well as the presence of restricted and repetitive facets of behavior, hobbies, or pursuits, which are often accompanied with cognitive limitations. Over the past few decades, a sizable number of studies have been conducted to enhance our understanding of the pathophysiology of ASD. Preclinical rat models have proven to be extremely valuable in simulating and analyzing the roles of a wide range of established environmental and genetic factors. Recent research has also demonstrated the significant involvement of the endocannabinoid system (ECS) in the pathogenesis of several neuropsychiatric diseases, including ASD. In fact, the ECS has the potential to regulate a multitude of metabolic and cellular pathways associated with autism, including the immune system. Moreover, the ECS has emerged as a promising target for intervention with high predictive validity. Particularly noteworthy are resent preclinical studies in rodents, which describe the onset of ASD-like symptoms after various genetic or pharmacological interventions targeting the ECS, providing encouraging evidence for further exploration in this area.

show abstract